Small-molecule aggregates are a leading cause of artifacts in early drug discovery, but little is known about their interactions with proteins, nor why some proteins are more susceptible to inhibition than others. A possible reason for this apparent selectivity is that aggregation-based inhibition, as a stoichiometric process, is sensitive to protein concentration, which varies across assays. Alternatively, local protein unfolding by aggregates may lead to selectivity since stability varies among proteins. To deconvolute these effects, we used differentially stable point mutants of a single protein, TEM-1 β-lactamase. Broadly, destabilized mutants had higher affinities for and were more potently inhibited by aggregates versus more stable va...
Drug discovery is fuelled by small-molecules, either as tools to interrogate biology or as leads for...
Small molecule aggregates are considered nuisance compounds in drug discovery, but their unusual pro...
Colloidal aggregates of small molecules are the most common artifact in early drug discovery, seques...
One of the leading sources of false positives in early drug discovery is the formation of organic sm...
One of the leading sources of false positives in early drug discovery is the formation of organic sm...
Early drug discovery is plagued by nonspecific molecules, which cannot be developed into drugs. Thes...
In the early phases of drug discovery, high-throughput screening (HTS) has emerged as the dominant t...
Small molecule colloidal aggregates adsorb and partially denature proteins, inhibiting them artifact...
Colloidal aggregates of small molecules are the most common artifact in early drug discovery, seques...
Solubility is a requirement for many cellular processes. Loss of solubility and aggregation can lead...
At micromolar concentrations, many small molecules self-associate into colloidal aggregates that non...
Although protein based therapeutics is the fastest growing sector of the pharmaceutical industry, pr...
Small molecule aggregates are considered nuisance compounds in drug discovery, but their unusual pro...
Increasing evidence links the misfolding and aberrant self-assembly of proteins with the molecular e...
Proteins perform their function in their native folded state. The native folded state of a protein ...
Drug discovery is fuelled by small-molecules, either as tools to interrogate biology or as leads for...
Small molecule aggregates are considered nuisance compounds in drug discovery, but their unusual pro...
Colloidal aggregates of small molecules are the most common artifact in early drug discovery, seques...
One of the leading sources of false positives in early drug discovery is the formation of organic sm...
One of the leading sources of false positives in early drug discovery is the formation of organic sm...
Early drug discovery is plagued by nonspecific molecules, which cannot be developed into drugs. Thes...
In the early phases of drug discovery, high-throughput screening (HTS) has emerged as the dominant t...
Small molecule colloidal aggregates adsorb and partially denature proteins, inhibiting them artifact...
Colloidal aggregates of small molecules are the most common artifact in early drug discovery, seques...
Solubility is a requirement for many cellular processes. Loss of solubility and aggregation can lead...
At micromolar concentrations, many small molecules self-associate into colloidal aggregates that non...
Although protein based therapeutics is the fastest growing sector of the pharmaceutical industry, pr...
Small molecule aggregates are considered nuisance compounds in drug discovery, but their unusual pro...
Increasing evidence links the misfolding and aberrant self-assembly of proteins with the molecular e...
Proteins perform their function in their native folded state. The native folded state of a protein ...
Drug discovery is fuelled by small-molecules, either as tools to interrogate biology or as leads for...
Small molecule aggregates are considered nuisance compounds in drug discovery, but their unusual pro...
Colloidal aggregates of small molecules are the most common artifact in early drug discovery, seques...